The
Food and Drug Administration granted Fast Track designation to Corbus
Pharmaceuticals Holdings Inc.'s (Nasdaq: CRBP) Resunab to treat systemic sclerosis sending the stock price soaring 64 cents to close at $2.50.
Corbus receives Fast Track designation
August 19, 2015 at 17:50 PM EDT
